VAERS Explorer
Back to explore

Report #2889452

Received Mar 18, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Unknown
Age
Age unknown
State
Recovered
Unknown
Vaccinated
Onset
Days to onset
Hospital days

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
TYPTYPHOID LIVE ORAL TY21A (VIVOTIF)BERNA BIOTECH, LTD.UNKUnknown

Symptoms (1)

Product administration error

Symptom narrative

The patient took Vivotif capsules with small breakfast and supposed to be taken on an empty stomach; Case reference number US-BN-2025-000395 is a spontaneous case report initially received from a physician via Communication (reference number: USBAV25-0644) on 21-Mar-2025 and concerns a patient of unspecified age and gender. The patient's relevant medical history and concomitant medications were not provided. On an unspecified date, the patient took unspecified number of doses of Vivotif vaccine (batch number: unknown) at an unknown dose or route of administration for unknown indication. The patient took Vivotif capsules with small breakfast (explicitly coded as 'product administration error'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. No further information was provided.; Reporter's Comments: A patient of unspecified age and gender took unspecified number of doses of Vivotif vaccine, at an unknown dose or route of administration for unknown indication. The patient took Vivotif capsules with small breakfast which is considered as product administration error. Product administration error is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A patient of unspecified age and gender took unspecified number of doses of Vivotif vaccine, at an unknown dose or route of administration for unknown indication. The patient took Vivotif capsules with small breakfast which is considered as product administration error. Product administration error is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.

Medical history

Comments: None.